Stanford study finds conventional methods may overestimate long COVID health effects
The gist
A Stanford study of 244 million Americans' insurance records found 98% fewer long-COVID-attributable outcomes than conventional methods.
The finding could reshape how long COVID research counts who is affected.
How it unfolded
- 2023BioVie received a Department of Defense grant through the Congressionally Directed Medical Research Programs, funding the $13 million ADDRESS-LC phase 2 trial of bezisterim.
- 2026 -09BioVie reported phase 2 trial results for bezisterim, which may improve Long COVID symptoms such as fatigue and post-exertional malaise as well as neurological symptoms.
- Oct 14, 2026A study finding patients with autoimmune rheumatic diseases have an increased risk for long COVID was published online in Arthritis & Rheumatology.